CARMIEL, Israel, June 23, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that new clinical data on ELELYSO™ and oral glucocerebrosidase (GCD), or oral GCD (PRX-112), will be presented at the European Working Group on Gaucher Disease 2014 11th Meeting being held June 25-28 in Haifa, Israel, at the Dan Carmel Hotel.
Professor Ari Zimran, M.D., Director of the Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel, is scheduled to deliver the following three oral presentations:
"Taliglucerase alfa in adult patients with Gaucher disease who were previously treated with imiglucerase: 36-month safety and efficacy results" on Friday, June 27 at 11:45 AM IDT.
"Taliglucerase alfa 36-month clinical safety and efficacy in treatment-naïve patients" on Friday, June 27 at 2:30 PM IDT.
"Novel treatment for Gaucher disease - oral administration of plant cells expressing GCD: Phase 1 study results and Phase 2a program" on Friday, June 27 at 3:30 PM IDT.
Additional information regarding the conference can be found at the official website for the meeting, http://ewggd2014-israel.com/.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012, by Israel's Ministry of Health in September 2012, by the Brazilian National Health Surveillance Agency (ANVISA) in March 2013, by the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) in April 2013, by the Australian Therapeutic Goods Administration (TGA) in May 2014 and by the regulatory authorities of other countries. Marketing applications for taliglucerase alfa have been filed in additional territories as well. Protalix has partnered with Pfizer Inc. for the worldwide development and commercialization of taliglucerase alfa, excluding Israel and Brazil, where Protalix retains full rights. Protalix's development pipeline includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-112, an orally-delivered glucocerebrosidase enzyme that is produced and encapsulated within carrot cells, for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel®) for the treatment of certain immune and inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, colitis, psoriasis and other autoimmune and inflammatory disorders; PRX-110 for the treatment of Cystic Fibrosis; and others.
CONTACT: Investor Contact Tricia Truehart The Trout Group, LLC 646-378-2953 email@example.com Media Contact Kari Watson MacDougall Biomedical Communications 781-235-3060 firstname.lastname@example.orgSource:Protalix BioTherapeutics, Inc.